ArticleInvestigational new drugs2017

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.

Alex A Adjei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.